317 related articles for article (PubMed ID: 28397102)
1. The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed.
Hernando-Cubero J; Matos-García I; Alonso-Orduña V; Capdevila J
J Gastrointest Cancer; 2017 Jun; 48(2):135-147. PubMed ID: 28397102
[TBL] [Abstract][Full Text] [Related]
2. New drugs in therapy of colorectal cancer: preclinical studies.
Rustum YM; Cao S
Semin Oncol; 1999 Dec; 26(6):612-20. PubMed ID: 10606254
[TBL] [Abstract][Full Text] [Related]
3. TAS-102: a novel antimetabolite for the 21st century.
Uboha N; Hochster HS
Future Oncol; 2016 Jan; 12(2):153-63. PubMed ID: 26616466
[TBL] [Abstract][Full Text] [Related]
4. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Emura T; Murakami Y; Nakagawa F; Fukushima M; Kitazato K
Int J Mol Med; 2004 Apr; 13(4):545-9. PubMed ID: 15010854
[TBL] [Abstract][Full Text] [Related]
5. Colon cancer: new drug options improve on 5-FU.
McCann J
J Natl Cancer Inst; 1998 Jul; 90(13):963-5. PubMed ID: 9665142
[No Abstract] [Full Text] [Related]
6. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.
Temmink OH; Emura T; de Bruin M; Fukushima M; Peters GJ
Cancer Sci; 2007 Jun; 98(6):779-89. PubMed ID: 17441963
[TBL] [Abstract][Full Text] [Related]
7. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.
Wilson PM; Danenberg PV; Johnston PG; Lenz HJ; Ladner RD
Nat Rev Clin Oncol; 2014 May; 11(5):282-98. PubMed ID: 24732946
[TBL] [Abstract][Full Text] [Related]
8. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance in colon cancer.
Gorlick R; Bertino JR
Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253
[TBL] [Abstract][Full Text] [Related]
10. TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies.
van der Velden DL; Opdam FL; Voest EE
Clin Cancer Res; 2016 Jun; 22(12):2835-9. PubMed ID: 27126991
[TBL] [Abstract][Full Text] [Related]
11. Oral fluoropoyrimidines.
Hoff PM; Royce M; Medgyesy D; Brito R; Pazdur R
Semin Oncol; 1999 Dec; 26(6):640-6. PubMed ID: 10606257
[TBL] [Abstract][Full Text] [Related]
12. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K
Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072
[TBL] [Abstract][Full Text] [Related]
13. Thymidine phosphorylase and capecitabine: a predictive marker for therapy selection?
O'Neil BH; McLeod HL
J Clin Oncol; 2006 Sep; 24(25):4051-3. PubMed ID: 16943521
[No Abstract] [Full Text] [Related]
14. TAS-102, a novel antitumor agent: a review of the mechanism of action.
Lenz HJ; Stintzing S; Loupakis F
Cancer Treat Rev; 2015 Nov; 41(9):777-83. PubMed ID: 26428513
[TBL] [Abstract][Full Text] [Related]
15. Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Koda K; Miyauchi H; Kosugi C; Kaiho T; Takiguchi N; Kobayashi S; Maruyama T; Matsubara H;
Anticancer Res; 2016 Oct; 36(10):5325-5331. PubMed ID: 27798895
[TBL] [Abstract][Full Text] [Related]
16. TAS-102 for the treatment of metastatic colorectal cancer.
Salvatore L; Rossini D; Moretto R; Cremolini C; Schirripa M; Antoniotti C; Marmorino F; Loupakis F; Falcone A; Masi G
Expert Rev Anticancer Ther; 2015; 15(11):1283-92. PubMed ID: 26509228
[TBL] [Abstract][Full Text] [Related]
17. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy.
Sobrero A; Guglielmi A; Grossi F; Puglisi F; Aschele C
Semin Oncol; 2000 Oct; 27(5 Suppl 10):72-7. PubMed ID: 11049035
[No Abstract] [Full Text] [Related]
19. New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.
van der Wilt CL; Peters GJ
Pharm World Sci; 1994 Apr; 16(2):84-103. PubMed ID: 7518280
[TBL] [Abstract][Full Text] [Related]
20. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]